# **Munich Cancer Registry**



- Incidence and Mortality
- Selection Matrix
- Homepage
- Deutsch

## **GIST: Gastroint. stromal tumor**

### Survival


Year of diagnosis	1998-2014
Patients	829
Diseases	830
Cases evaluated	605
Creation date	04/11/2016
Export date	12/23/2015
Population	4.64 m



Munich Cancer Registry at Munich Cancer Center Marchioninistr. 15 Munich, 81377 Germany

http://www.tumorregister-muenchen.de/en

http://www.tumorregister-muenchen.de/en/facts/surv/shGISTE-GIST-Gastroint.-stromal-tumor-survival.pdf




**Figure 1a.** Relative survival of patients with gastroint. stromal tumor by period of diagnosis. Included in the evaluation are 600 cases diagnosed between 1998 and 2014.

The presented survival curves are derived from clinical records with valid follow-up informations, which means that death certificate cases (DCO) cases are omitted from the analysis. With this one restriction, the MCR has provided populationbased statistics since 1998, collecting data on all cancer cases in the region of southern Bavaria. Historical data of previous time periods can be heavily selected, therefore, univariate survival comparisons of the presented time periods must be carefully considered. Nonetheless, all calculable survival curves are depicted to facilitate the comparison of long time follow-up analyses of relative survival between particular cancers.

Period of diagnosis									
	1998-	2006	2007+						
	n=1	171	n=429						
Years	obs. %	rel. %	obs. %	rel. %					
0	100.0	100.0	100.0	100.0					
1	84.0	86.0	93.1	95.4					
2	76.9	79.8	91.0	94.9					
3	72.2	76.9	86.3	92.7					
4	67.4	72.7	83.7	92.1					
5	61.4	68.0	81.4	91.3					

**Table 1b.** Observed (obs.) and relative (rel.) survival of patients with gastroint. stromal tumor by period of diagnosis for period 1998-2014 (N=600).




**Figure 2a.** Survival of patients with gastroint. stromal tumor by gender. Included in the evaluation are 600 cases diagnosed between 1998 and 2014.

Gender								
	Ma n=3		Female n=290					
Years	obs. %							
0	100.0	100.0	100.0	100.0				
1	92.0	94.1	88.7	90.6				
2	86.3	90.6	87.0	90.4				
3	81.5	88.0	82.2	87.0				
4	78.5	86.7	77.6	83.7				
5	74.2	83.8	72.8	80.6				

**Table 2b.** Observed (obs.) and relative (rel.) survival of patients with gastroint. stromal tumor by gender for period 1998-2014 (N=600).






**Figure 2c.** Conditional relative 2 / 5-year survival of patients with gastroint. stromal tumor by gender. For 600 of 600 cases diagnosed between 1998 and 2014 valid data could be obtained for this item.

		G	Sender	•		
	Male			Female		
		Cond. s	surv. %		Cond. s	urv. %
Years	n	2 yrs	5 yrs	n	2 yrs	5 yrs
0	310	90.6	83.9	290	90.4	80.6
1	254	93.5	84.2	227	96.1	86.5
2	211	95.6	85.2	200	92.5	86.5
3	170	95.3	88.8	159	92.6	87.3
4	116	91.1	85.9	124	93.4	89.4
5	86	91.5	87.1	97	97.6	93.6
6	59	98.0	91.5	74	97.5	95.4
7	47	96.5		60	95.2	
8	38	92.2		47	98.2	
9	33	96.9		39	99.6	

**Table 2d.** Conditional relative 2 / 5-year survival of patients with gastroint. stromal tumor by gender for period 1998-2014 (N=600).

Conditional relative survival rates refer to the relative survival probability, in this case for 2 and 5 years after cancer diagnosis, compared to the age- and sex-matched population (=100%) under the condition of being alive for a certain time period (x-axis in Figure 2a). The results illustrate to what extent the cancer induced mortality of particular subgroups declines in the subsequent years after detection of the malignancy. For instance, according to the presented survival statistics, patients in the subgroup gender="Male", who are alive at least 3 years after cancer diagnosis, the conditional relative 2-year survival rate is 95.3% (n=170).




**Figure 3a.** Relative survival of patients with gastroint. stromal tumor by age category. Included in the evaluation are 600 cases diagnosed between 1998 and 2014.

Age category									
	0-49	) yrs	50-59	9 yrs	60-69	9 yrs	70+	yrs	
	n=	88	n=1	n=111		n=179		222	
Years	obs. %	rel. %							
0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	
1	96.3	96.1	99.0	99.2	90.6	91.6	83.6	88.0	
2	96.3	95.3	95.8	96.8	86.5	88.0	78.4	86.0	
3	89.2	89.4	95.8	96.6	81.7	84.3	72.0	84.3	
4	87.3	87.0	88.6	90.5	78.9	82.3	68.7	84.3	
5	87.3	85.9	82.1	83.6	72.5	77.5	65.5	83.1	

**Table 3b.** Observed (obs.) and relative (rel.) survival of patients with gastroint. stromal tumor by age category for period 1998-2014 (N=600).






**Figure 4a.** Relative survival of patients with gastroint. stromal tumor by histology. For 598 of 600 cases diagnosed between 1998 and 2014 valid data could be obtained for this item. Subgroups with sample size <15 are dropped from the chart.

Histology GI stromal tumor, NOS GI stromal sarcoma n=7 n=591						
Years	obs. %	rel. %	obs. %	rel. %		
0	100.0	100.0	100.0	100.0		
1			90.8	93.0		
2			86.9	91.0		
3			82.1	88.0		
4			78.2	85.7		
5			73.5	82.5		

**Table 4b.** Observed (obs.) and relative (rel.) survival of patients with gastroint. stromal tumor by histology for period 1998-2014 (N=598).






**Figure 4c.** Relative survival of patients with gastroint. stromal tumor by extent of disease. For 320 of 600 cases diagnosed between 1998 and 2014 valid data could be obtained for this item. For a total of 302 cases an evaluable classification was established. The grey line represents the subgroup of 298 patients with missing values regarding extent of disease (49.7% of 600 patients, the percent values of all other categories are related to n=302). Subgroups with sample size <15 are dropped from the chart.

Extent of disease								
	Loc	cal	Regional		Distant		NA/NOS	
	n=216		n=9		n=77		n=298	
Years	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
1	92.9	94.8			77.3	78.5	92.7	94.8
2	91.5	94.7			67.6	70.0	89.1	93.4
3	88.9	94.4			59.0	62.3	84.3	90.8
4	84.6	92.3			52.7	55.4	81.2	89.5
5	81.6	87.3			47.6	51.7	77.2	86.9
	0 1 2 3 4	n=2   Years obs. %   0 100.0   1 92.9   2 91.5   3 88.9   4 84.6	Years obs. % rel. %   0 100.0 100.0   1 92.9 94.8   2 91.5 94.7   3 88.9 94.4   4 84.6 92.3	Local Regineration   Years obs.% rel.% obs.%   0 100.0 100.0 100.0   1 92.9 94.8 100.0   2 91.5 94.7 100.0   3 88.9 94.4 100.0   4 84.6 92.3 100.0	Local Regional   n=216 n=9   Years obs.% rel.% obs.% rel.%   0 100.0 100.0 100.0 100.0   1 92.9 94.8 100.0 100.0   2 91.5 94.7 100.0 100.0   3 88.9 94.4 100.0 100.0   4 84.6 92.3 100.0 100.0	$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Local Regional Distant   n=216 n=9 05.% rel.%   obs.% rel.% obs.% rel.% obs.% rel.%   0 100.0 100.0 100.0 100.0 100.0 100.0   1 92.9 94.8 77.3 78.5   2 91.5 94.7 67.6 70.0   3 88.9 94.4 59.0 62.3   4 84.6 92.3 67.6 52.7	Local Regional Distant NA/N   n=216 n=9 0b. % n=7 n=2   Years obs. % rel. %

**Table 4d.** Observed (obs.) and relative (rel.) survival of patients with gastroint. stromal tumor by extent of disease for period 1998-2014 (N=302).






**Figure 5a.** Time to first progression of 518 patients with gastroint. stromal tumor diagnosed between 1998 and 2014 (M0 only in solid cancers) estimated by cumulative incidence function (CI, solid line) accounting for death as competing risk and by inverse Kaplan-Meier estimate (1-KM, dashed line). The frequency of events may be underestimated due to underreporting.

Type of progression							
	Any type (CI)	Any type (1-KM)					
	n=518	n=518					
Years	%	%					
0	0.0	0.0					
1	7.1	7.4					
2	13.1	13.7					
3	16.8	17.7					
4	19.9	21.2					
5	22.7	24.5					

**Table 5b.** Time to first progression of patients with gastroint. stromal tumor for period 1998-2014 (N=518).






**Figure 5c.** Observed post-progression survival of 143 patients with gastroint. stromal tumor diagnosed between 1998 and 2014. These 143 patients with documented progression events during their course of disease represent 24.1 % of the totally 593 evaluated cases (incl. M1, n=75, 12.6 %). Patients with cancer relapse documented via death certificates only were excluded (n=29, 4.9 %).

Medical record documentation often lacks the linguistic severity to distinguish between local relapse, regional lymph node metastasis and distant spread in solid cancers. Frequently, the statement "not specified" is the only information in registries regarding relapse of the disease. The category "Any type" denotes all cases who suffered from at least one relapse during the course of disease (incl. primary M1-status). Although, the real number of relapsed patients is likely to be much higher. The accumulated percentage of patients with local relapse or distant metastasis exceeds the 100% value because patients are potientially considered in more than one subgroup.

	ype of gression	
	Any type n=143	
Years	%	
0	100.0	
1	80.4	
2	71.0	
3	61.7	
4	54.4	
5	49.5	
6	45.2	
7	40.4	
8	38.6	
9	34.1	
10	34.1	

**Table 5d.** Observed post-progression survival of patients with gastroint. stromal tumor for period 1998-2014 (N=143).



**Figure 5e.** Observed post-progression (distant metastasis) survival of 122 patients with gastroint. stromal tumor diagnosed between 1998 and 2014 by period of progression.

P	eriod of prog	ression	
	1998-2006	2007+	
	n=56	n=66	
Years	%	%	
0	100.0	100.0	
1	75.0	80.3	
2	62.5	73.1	
3	50.0	64.8	
4	42.9	59.5	
5	37.5	59.5	
6	32.1	59.5	
7	26.8	59.5	

**Table 5f.** Observed post-progression (distant metastasis) survival of patients with gastroint. stromal tumor for period 1998-2014 by period of progression (N=122).



#### Shortcuts

MCR	Munich Cancer Registry, Germany							
NCI	National Cancer Institute, USA							
SEER	Surveillance, Epidemiology	, and End Results, USA						
UICC	Union for International Can	cer Control, Geneva						
DCO	Death certificate only	Death certificate provides the only notification to the registry.						
NA	Not available							
NOS	Not otherwise specified							
OS	Overall/Observed survival	Overall/Observed survival (Kaplan-Meier estimate) Date of entry: diagnosis Event: death from any cause						
RS	Relative survival	Survival compared to "general population", ratio of observed to expected survival (Ederer II method), reflecting cancer specific survival						
AS	Assembled survival	Assembled chart of observed, expected, relative survival						
CS	Conditional survival	Survival probability under the condition of surviving a given period of time						
TTP	Time to progression	Time to first progression / relapse Date of entry: diagnosis Event: (progression / relapse): first local-, lymph node recurrence, distant metastasis or unspecified progression						
	1-КМ	1 minus Kaplan-Meier estimator ("inverse" Kaplan-Meier estimator)						
	CI	Cumulative incidence Death as competing risk (according to Kalbfleisch und Prentice)						
PPS	Post-progression survival	Survival since first progression / relapse (Kaplan-Meier estimate) Date of entry (progression / relapse): first local-, lymph node recurrence, distant metastasis or unspecified progression Event: death from any cause						

#### **Recommended Citation**

Munich Cancer Registry. Survival GIST: Gastroint. stromal tumor [Internet]. 2016 [updated 2016 Apr 11; cited 2016 Jun 1]. Available from: http://www.tumorregister-muenchen.de/en/facts/surv/shGISTE-GIST-Gastroint.-stromal-tumor-survival.pdf

#### Copyright

The content of the public web site provided by the Munich Cancer Registry is available worldwide and free of charge. All documents are free to download, utilize, copy, print-out and distribute, providing that the MCR is referenced.

#### Disclaimer

The Munich Cancer Registry reserves the right to not be responsible for the topicality, correctness, completeness or quality of the information provided. Liability claims regarding damage caused by the use of any information provided, including any kind of information which is incomplete or incorrect, will therefore be rejected.

### Index of figures and tables

Fig./Tb	bl.	Page
1a	Relative survival by period of diagnosis (chart)	2
1b	Survival by period of diagnosis (table)	2
2a	Survival by gender (chart)	3
2b	Survival by gender (table)	3
2c	Conditional survival by gender (chart)	4
2d	Conditional survival by gender (table)	4
3a	Relative survival by age category (chart)	5
3b	Survival by age category (table)	5
4a	Relative survival by histology (chart)	6
4b	Survival by histology (table)	6
4c	Relative survival by extent of disease (chart)	7
4d	Survival by extent of disease (table)	7
5a	Time to first progression (chart)	8
5b	Time to first progression (table)	8
5c	Observed post-progression survival (chart)	9
5d	Observed post-progression survival (table)	9
5e	Observed post-progression survival by period of progression (chart)	10
5f	Observed post-progression survival by period of progression (table)	10